Singapore markets open in 54 minutes

Xencor, Inc. (XNCR)

NasdaqGM - NasdaqGM Real-time price. Currency in USD
Add to watchlist
32.90-2.30 (-6.53%)
At close: 04:00PM EST
32.86 -0.04 (-0.12%)
After hours: 04:56PM EST
Full screen
Trade prices are not sourced from all markets
Previous close35.20
Open34.63
Bid32.75 x 1100
Ask51.27 x 800
Day's range32.89 - 34.86
52-week range30.12 - 58.35
Volume795,633
Avg. volume264,925
Market cap1.924B
Beta (5Y monthly)0.76
PE ratio (TTM)N/A
EPS (TTM)-0.07
Earnings date21 Feb 2022 - 25 Feb 2022
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est55.00
  • Business Wire

    Xencor Highlights 2022 Corporate Priorities and Portfolio Milestones

    MONROVIA, Calif., January 11, 2022--Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies and cytokines for the treatment of cancer and autoimmune diseases, today announced 2022 corporate priorities and anticipated clinical development and research milestones.

  • Business Wire

    Xencor to Present at the H.C. Wainwright Bioconnect Virtual Conference

    MONROVIA, Calif., January 06, 2022--Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies and cytokines for the treatment of cancer and autoimmune diseases, today announced that company management will participate in a pre-recorded fireside chat at the H.C. Wainwright Bioconnect Virtual Conference.

  • Business Wire

    Xencor Presents Data from Phase 1 Study of Plamotamab in B-cell Non-Hodgkin Lymphomas at the ASH Annual Meeting

    MONROVIA, Calif., December 12, 2021--Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies and cytokines for the treatment of cancer and autoimmune diseases, today announced updated data from its Phase 1 dose-escalation study of plamotamab, a CD20 x CD3 bispecific antibody, in patients with B-cell non-Hodgkin lymphomas. Data will be presented by Krish Patel, M.D., Director of the Lymphoma Program at Swedish Cancer Institute, in a poste